Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haploidentical stem cell transplantation in leukemia.

F Aversa1, A Velardi, A Tabilio

  • 1Hematopoietic Stem Cell Program, Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, 06100, Italy. aversa@unipg.it

Blood Reviews
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.

Bone marrow transplantation·2023
Same author

Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases.

Mycoses·2018
Same author

Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.

Annals of hematology·2018
Same author

Jon van Rood (1926-2017).

Bone marrow transplantation·2017
Same author

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Haploidentical stem cell transplants, using T-cell depleted grafts, are a viable treatment for acute leukemia patients, preventing graft-vs-host disease and improving engraftment. This approach offers a crucial alternative when matched donors are unavailable.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Acute leukemia treatment often requires hematopoietic stem cell transplantation.
  • Finding a matched donor can be a significant challenge for many patients.
  • Haploidentical (half-matched) transplants offer a potential alternative.

Purpose of the Study:

  • To evaluate the efficacy of T-cell depleted haploidentical stem cell transplantation in acute leukemia.
  • To assess engraftment, graft-vs-host disease, and relapse rates.
  • To establish haploidentical transplantation as a clinical reality for high-risk patients.

Main Methods:

  • Immuno-myeloablative conditioning regimen followed by infusion of megadose T-cell depleted hematopoietic stem cells.
  • Focus on optimizing graft processing and post-transplant immunological recovery.

Related Experiment Videos

  • Utilizing donor natural killer cell alloreactivity to enhance engraftment and prevent relapse.

    • Main Results:

    • Sustained engraftment achieved in full-haplotype mismatched transplants.
    • Absence of graft-vs-host disease in treated patients.
    • Successful application in 112 very high-risk acute leukemia patients, demonstrating clinical feasibility.

    Conclusions:

    • T-cell depleted haploidentical stem cell transplantation is a safe and effective treatment for acute leukemia.
    • This approach should be considered a primary option, not a last resort, for patients lacking matched donors.
    • The availability of immediate, haploidentical donors makes this a widely accessible therapeutic strategy.